Streetbeat News

Revenues

SFT

Shift4 has experienced significant growth under CEO Jared Isaacman, with revenues increasing from $766M to $2.5B since 2020. Isaacman's potential departure for a NASA role poses a risk to the company's continued success.

Portfolio Pulse from

December 07, 2024 | 7:15 am

KYMR

Kymera Therapeutics' KT-474, in partnership with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion expected by mid-2026. KT-621 shows promise for immuno-inflammatory disorders with Phase 1 data expected in 2025. Kymera has $911 million in cash, funding operations into mid-2027.

Portfolio Pulse from

December 07, 2024 | 6:30 am

LSPD

Lightspeed Commerce is experiencing revenue growth and improved market presence due to its unified offerings and focus on high GTV customers. The company is reorganizing and implementing a share repurchase program to enhance profitability and valuation, supported by a strong cash balance and no long-term debt. Despite conservative analyst targets, Lightspeed's growing adjusted EBITDA and attractive EV/Sales multiples suggest long-term growth potential, particularly in North American retail and EMEA hospitality markets.

Portfolio Pulse from

December 07, 2024 | 4:30 am

HPE

Hewlett Packard Enterprise (HPE) reported better-than-expected fiscal Q4 earnings, with record-high revenue of $8.46 billion, up 15% year over year, and adjusted earnings of $0.58 per share. This led to a 10% increase in HPE's stock price.

Portfolio Pulse from

December 07, 2024 | 1:30 am

BHC

BLCO

Bausch Health Companies Inc. is considering the sale of Bausch + Lomb Corporation to address its significant debt burden. Bausch + Lomb showed revenue growth and a shift to net income in Q3, driven by new products. Despite bankruptcy rumors, strategic moves by major investors could prevent such an outcome.

Portfolio Pulse from

December 07, 2024 | 12:45 am

MFIC

MidCap Financial Investment, a BDC, is offering an 11% yield with an 86% payout ratio and is trading at a 7% discount to its net asset value. The company has a stable dividend policy and potential for future special dividends due to its strategic investments and improved non-accrual ratio.

Portfolio Pulse from

December 06, 2024 | 11:45 pm

VSCO

Victoria's Secret & Co. reported a 3% increase in comparable sales for Q3 2024, driven by international sales. The stock has surged 200% since the new CEO's appointment, raising concerns of overvaluation despite improved guidance. Investors need to believe in sustained revenue growth and margin doubling for decent returns, which is risky.

Portfolio Pulse from

December 06, 2024 | 10:45 pm

GEHC

GE HealthCare Technologies is rated a buy due to strong growth prospects, a healthy backlog, and favorable valuation. Revenue growth is driven by new product innovations and potential recovery in Chinese demand. Margins are expected to improve through cost optimization and strategic pricing.

Portfolio Pulse from

December 06, 2024 | 10:45 pm

LULU

The S&P 500 had mixed results as the first week of December concluded. Lululemon's stock saw significant gains due to a positive holiday sales outlook.

Portfolio Pulse from

December 06, 2024 | 10:30 pm